Summit Therapeutics Inc.

NasdaqGM:SMMT 주식 보고서

시가총액: US$14.7b

Summit Therapeutics 관리

관리 기준 확인 2/4

Summit Therapeutics CEO는 Bob Duggan, Jul2022 에 임명되었습니다 의 임기는 2.33 년입니다. 는 $ 11.03B 가치에 해당하는 회사 주식의 74.81% 직접 소유합니다. 11.03B. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 4.5 년입니다.

주요 정보

Bob Duggan

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기2.3yrs
CEO 소유권74.8%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간4.5yrs

최근 관리 업데이트

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics May Have Further Upside From Here

Aug 03

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

May 06

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

CEO

Bob Duggan (80 yo)

2.3yrs

테뉴어

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...

리더십 팀

이름위치테뉴어보상소유권
Robert Duggan
Co-CEO & Executive Chairman2.3yrs데이터 없음74.81%
$ 11.0b
Mahkam Zanganeh
Co-CEO, President & Director2.3yrsUS$20.56m4.85%
$ 714.8m
Manmeet Soni
COO, CFO & Director1.1yrsUS$23.97m0.41%
$ 60.4m
Dame Davies
Co-Founderno data데이터 없음데이터 없음
Bhaskar Anand
Chief Accounting Officer & Head of Financeless than a year데이터 없음0.018%
$ 2.6m
Abby Murphy
Head of Human Resources1.6yrs데이터 없음데이터 없음
Divya Chari
Head of Global Clinical Operations4.7yrs데이터 없음데이터 없음
Dave Gancarz
Chief Business & Strategy Officerno data데이터 없음데이터 없음
Betty Chang
Head of Research3.4yrs데이터 없음데이터 없음
Fong Clow
Chief Biometrics Officer3.8yrs데이터 없음데이터 없음
Shelley Spray
Chief Education & Brand Officer1.8yrs데이터 없음데이터 없음
Juthamas Sukbuntherng
Head of Clinical Pharmacology & DMPK3.3yrs데이터 없음데이터 없음

2.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: SMMT 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Robert Duggan
Co-CEO & Executive Chairman4.9yrs데이터 없음74.81%
$ 11.0b
Mahkam Zanganeh
Co-CEO, President & Director4yrsUS$20.56m4.85%
$ 714.8m
Manmeet Soni
COO, CFO & Director4.9yrsUS$23.97m0.41%
$ 60.4m
Dame Davies
Co-Founderno data데이터 없음데이터 없음
Kenneth Clark
Lead Independent Director3.1yrsUS$334.65k데이터 없음
Marcel van den Heuvel
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Francesco Muntoni
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Roger Patient
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Edith Sim
Member of Scientific Advisory boardno data데이터 없음데이터 없음
Bob Sim
Member of Scientific Advisory boardno data데이터 없음데이터 없음
Derek Stemple
Member of Scientific Advisory boardno data데이터 없음데이터 없음
Jean-Paul Vincent
Member of Scientific Advisory boardno data데이터 없음데이터 없음

4.5yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: SMMT 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.